CJC-1295 (No DAC) / GHRP-2 Blend is a research peptide formulation combining two well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: CJC-1295 without Drug Affinity Complex (No DAC) and Growth Hormone–Releasing Peptide-2 (GHRP-2). CJC-1295 (No DAC) is a modified growth hormone–releasing hormone (GHRH) analog, while GHRP-2 is a potent growth hormone secretagogue receptor (GHS-R) agonist. Together, this blend is formulated for laboratory research focused on pulsatile growth hormone release, receptor signaling pathways, and metabolic regulation mechanisms.
Prior to the targeted development and isolation of these peptides, research into growth hormone stimulation relied largely on less selective secretagogues and broader hormonal interventions. In controlled research settings, CJC-1295 (No DAC) has been studied for its ability to stimulate endogenous growth hormone release via GHRH receptor activation while maintaining a shorter duration of action compared to DAC-bound variants. GHRP-2 has been widely researched for its strong receptor binding activity and its role in stimulating growth hormone secretion through ghrelin receptor pathways. The combination allows researchers to examine complementary mechanisms involved in growth hormone pulsatility, amplitude, and signaling dynamics.
Currently, the CJC-1295 (No DAC) / GHRP-2 Blend is being investigated for its potential applications in metabolic research models, endocrine pathway analysis, recovery-related signaling studies, and age-associated hormone regulation research. Additional studies continue to explore its role in downstream anabolic signaling, circadian hormone patterns, and coordinated pituitary response mechanisms. Due to the complementary research interest of these peptides, this blend remains a valuable subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The CJC-1295 (No DAC), GHRP-2 Blend is designed for laboratory programs studying growth hormone signaling pathways, endocrine communication dynamics, and pulsatile hormonal responses under controlled research conditions. Pairing a growth hormone–releasing hormone (GHRH) analog with a growth hormone secretagogue allows investigators to evaluate how upstream hypothalamic signaling interacts with downstream pituitary response behavior within experimental models.
In experimental frameworks, blends like this are often used to analyze signal amplification, pulse-pattern behavior, and biomarker movement over defined time intervals. Because multi-variable peptide research introduces additional interpretation complexity, well-designed protocols emphasize strict endpoint definitions, consistent sampling intervals, and tight environmental controls to preserve data integrity.
CJC-1295 (No DAC), GHRP-2 Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | CJC-1295 (No DAC) + GHRP-2 |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
CJC-1295 without DAC is commonly discussed in research literature as a modified GHRH analog used in experimental designs investigating pulsatile growth hormone release signaling. Because the compound lacks the Drug Affinity Complex (DAC) modification found in some variants, it is often studied in contexts where researchers want to observe shorter signaling windows and clearer pulse-response relationships.
GHRP-2 is frequently referenced in peptide research as a growth hormone secretagogue that interacts with ghrelin receptor pathways and pituitary response mechanisms. In controlled experimental models, it may be included in designs that track endocrine response markers, metabolic variables, and signaling cascades associated with GH-related pathways.
When combined, CJC-1295 (No DAC) and GHRP-2 allow researchers to examine how GHRH signaling and secretagogue pathways interact. Some experimental frameworks investigate whether dual-pathway stimulation produces measurable differences in pulse amplitude, frequency, or downstream biomarker changes compared to single-variable models.
For researchers evaluating individual pathways independently, separate sourcing references are available for CJC-1295 (without DAC) and GHRP-2.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
One of the primary applications of this blend in research environments involves studying pulsatile growth hormone signaling patterns. Researchers may evaluate how combined upstream and downstream pathway activation influences marker movement within time-series sampling frameworks.
Because both peptides interact with components of the GH-axis, they are frequently used in endocrine signaling research to observe pituitary responsiveness and hormone signaling cascades. Controlled experimental designs can track how signaling pathways interact under standardized conditions.
Some laboratories conduct comparative experiments where a blended protocol is evaluated alongside individual peptide variables. This design helps researchers distinguish between additive signaling effects and independent pathway behavior while reducing interpretive bias.
Growth hormone signaling research often overlaps with metabolic marker panels and body composition models in controlled environments. In these contexts, researchers may analyze downstream variables such as lipid metabolism markers, endocrine readouts, or cellular signaling indicators that change alongside GH-axis activity.
The CJC-1295 (No DAC), GHRP-2 Blend should be handled using standard laboratory peptide protocols that emphasize storage integrity, contamination prevention, and detailed experimental documentation. As with many endocrine signaling variables, maintaining consistent environmental conditions and timing parameters improves research reproducibility.
Protocol Design Considerations: Growth hormone signaling experiments are sensitive to circadian rhythm timing, baseline metabolic phenotype, stress variables, and environmental stability. Consistent sampling windows and controlled laboratory conditions are essential for reliable data interpretation.
Note: The information above is provided solely as a research reference summary. All experimental work must be performed by qualified professionals in appropriately equipped laboratory environments.
Each lot of this peptide blend is supported by a Certificate of Analysis documenting identity and quality parameters. COAs assist research teams with internal documentation, procurement verification, and reproducibility tracking across study phases.
When sourcing peptides for endocrine pathway research, laboratories typically prioritize traceable lot documentation, reliable quality control processes, and consistent product identity verification. Nordsci Peptides provides research-grade peptide materials supported by analytical documentation and structured procurement processes designed to support reproducibility-focused research environments.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or medical use. Researchers are responsible for ensuring compliance with all applicable regulatory and institutional guidelines.
